Drug Trial Radar · NCT01270464
A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma
Last checked: Nov 20, 2026Latest source record: Jun 6, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
315
Actual
Start
Feb 2011
Primary completion
Sep 2013
Study completion Sep 2013
Sponsor
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
- Sponsor type
- Industry
- First posted
- Jan 5, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to determine whether reslizumab, at a dosage of 0.3 or 3.0 mg/kg administered once every 4 weeks for a total of 4 doses, is more effective than placebo in improving lung function in patients with eosinophilic asthma as assessed by the overall change from baseline in forced expiratory volume in 1 second (FEV1).
Conditions
- Eosinophilic Asthma
Interventions
ReslizumabDrug
3.0 mg/kg or 0.3 mg/kg doses administered intravenously (iv) by qualified site personnel once every 4 weeks, for a total of 4 doses.
PlaceboDrug
Placebo administered by iv infusion by qualified study personnel every 4 weeks for a total of 4 doses.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline In Forced Expiratory Volume In 1 Second (FEV1) Over 16 Weeks Using Mixed Model for Repeated MeasuresTime frame: Day 0 (baseline, pre-dose), Weeks 4, 8, 12 and 16
Locations
89 sites in 13 countries. Site status is shown where the registry gives one.
Teva Investigational Site 12
Anaheim, California
Teva Investigational Site 11
Fountain Valley, California
Teva Investigational Site 43
Los Angeles, California
Teva Investigational Site 4
Orange, California
Teva Investigational Site 15
Walnut Creek, California
Teva Investigational Site 2
Colorado Springs, Colorado
Teva Investigational Site 24
Largo, Florida
Teva Investigational Site 27
Miami, Florida
Teva Investigational Site 5
Miami, Florida
Teva Investigational Site 19
Tallahassee, Florida
Teva Investigational Site 17
Trinity, Florida
Teva Investigational Site 18
Valrico, Florida
Teva Investigational Site 6
Lilburn, Georgia
Teva Investigational Site 3
Savannah, Georgia
Teva Investigational Site 7
Iowa City, Iowa
Teva Investigational Site 8
Omaha, Nebraska
Teva Investigational Site 26
Summit, New Jersey
Teva Investigational Site 20
Cincinnati, Ohio
Teva Investigational Site 1
Medford, Oregon
Teva Investigational Site 73
Lincoln, Rhode Island
Teva Investigational Site 9
Providence, Rhode Island
Teva Investigational Site 21
Charleston, South Carolina
Teva Investigational Site 16
Fort Worth, Texas
Teva Investigational Site 10
Houston, Texas
Teva Investigational Site 14
San Antonio, Texas
Teva Investigational Site 45
San Antonio, Texas
Teva Investigational Site 121
Ciudad Autonoma de Buenos Aire, Argentina
Teva Investigational Site 126
Ciudad Autonoma de Buenos Aire, Argentina
Teva Investigational Site 127
Ciudad Autonoma de Buenos Aire, Argentina
Teva Investigational Site 128
Quilmes-Buenos Aires, Argentina
Teva Investigational Site 125
Rosario, Argentina
Teva Investigational Site 123
Rosario-Santa Fe, Argentina
Teva Investigational Site 120
San Miguel de Tucuman - Tucuma, Argentina
Teva Investigational Site 122
San Miguel de Tucuman - Tucuma, Argentina
Teva Investigational Site 124
San Miguel de Tucuman - Tucuma, Argentina
Teva Investigational Site 261
Brussels, Belgium
Teva Investigational Site 264
Brussels, Belgium
Teva Investigational Site 260
Ghent, Belgium
Teva Investigational Site 263
Liège, Belgium
Teva Investigational Site 146
Belo Horizonte, Brazil
Showing 40 of 89 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.